CALDEROL SOLUTION FOR I.V. INJECTION 1 MCG/ML [SIN17633P]
Active ingredients: CALCITRIOL
Product Info
CALDEROL SOLUTION FOR I.V. INJECTION 1 MCG/ML
[SIN17633P]
Product information
Active Ingredient and Strength | CALCITRIOL - 1 MCG/ML |
Dosage Form | INJECTION, SOLUTION |
Manufacturer and Country | DEM İLAÇ SANAYI VE TICARET A.Ş. - TURKEY |
Registration Number | SIN17633P |
Licence Holder | NOVEM HEALTHCARE PTE LTD |
Forensic Classification | PRESCRIPTION ONLY MEDICINES |
Anatomical Therapeutic Chemical (ATC) code | A11CC04 |
Prescription-only Medicines with Exemptions for Supply without Prescription | NA |
Indication
4.1. Therapeutic indications
CALDEROL is used in the management of hypocalcemia in patients undergoing chronic renal dialysis. It has been shown to significantly reduce elevated parathyroid hormone levels. Reduction of PTH has been shown to result in an improvement in renal osteodystrophy.
Dosing
4.2. Posology and method of administration
Posology:
CALDEROL is for intravenous injection only.
The optimal dose of CALDEROL must be carefully determined for each patient.
The effectiveness of CALDEROL therapy is predicated on the assumption that each patient is receiving an adequate and appropriate daily intake of calcium. To ensure that each patient receives an adequate daily intake of calcium, the physician should either prescribe a calcium supplement or instruct the patient in proper dietary measures.
The recommended initial dose of CALDEROL, depending on the severity of the hypocalcemia and/or secondary hyperparathyroidism, is 1 mcg (0.02 mcg/kg) to 2 mcg administered intravenously three times weekly, approximately every other day. Doses as small as 0.5 mcg and as large as 4 mcg three times weekly have been used as an initial dose. If a satisfactory response is not observed, the dose may be increased by 0.5 to 1 mcg at two to four week intervals. During this titration period, serum calcium and phosphorus levels should be obtained at least twice weekly. If hypercalcemia or a serum calcium times phosphate product greater than 70 is noted, the drug should be immediately discontinued until these parameters are appropriate. Then, the CALDEROL dose should be reinitiated at a lower dose. Doses may need to be reduced as the PTH levels decrease in response to the therapy. Thus, incremental dosing must be individualized and commensurate with PTH, serum calcium and phosphorus levels. The following is a suggested approach in dose titration:

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
Route of Administration:
CALDEROL should only be given as intravenous injection.
Ampoules are for single use only. The unused portion should be discarded.
Additional Information for Special Populations:
Pediatric Use
Safety and efficacy of Calcitriol injection in paediatric patients have not been established.
Geriatric Use
Clinical studies of Calcitriol injection did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.
In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosage range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
Contraindications
4.3. Contraindications
CALDEROL should not be given to patients with hypercalcemia or evidence of vitamin D toxicity.
CALDEROL is contraindicated in patients with previous hypersensitivity to calcitriol or any of its excipients.
